The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The clinical activity of imetelstat in patients with MDS and anemia
Moshe Mittelman, MD, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, comments on the clinical activity of imetelstat in treating anemia of myelodysplastic syndromes (MDS), noting that the telomerase inhibitor has shown effectiveness in approximately 40-50% of patients resistant to prior treatments. The IMerge study (NCT02598661), which was recently published, has already led to Food & Drug Administration (FDA) approval, with expected approval by the European Medicines Agency (EMA) in the near future. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
Yes, actually you are referring to a very specific study. I would, with your permission, a little bit extend it. Over the last decade or couple of decades, we have had several agents which are effective to treat the anemia of MDS. Imetelstat is probably the third or the fourth and it is a new class and the effect of the mechanism of which is telomerase inhibitor. So this is the new drug affecting in another mechanism...
Yes, actually you are referring to a very specific study. I would, with your permission, a little bit extend it. Over the last decade or couple of decades, we have had several agents which are effective to treat the anemia of MDS. Imetelstat is probably the third or the fourth and it is a new class and the effect of the mechanism of which is telomerase inhibitor. So this is the new drug affecting in another mechanism. It has been shown to be effective in about 40 to 50 percent of patients who were resistant to prior treatments. So definitely this is a new development, very encouraging, and we have additional agents to offer our patients. This particular study represents a study which was called IMerge. The study was published a few months ago. The agent has already been approved by FDA and it’s going to be approved hopefully very soon by EMA and other countries as well. And yes, we have another agent to treat our patients with anemia related to MDS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
FibroGen: Other: Speaker; Abbvie: Research Funding; BMS: Research Funding; Novartis: Research Funding; Johnson & Johnson: Research Funding; CannaLean: Other: Shares; Dr. Reddy: Consultancy; BioConvergence: Consultancy; Roche: Research Funding.
